BAXTER INTERNATIONAL INC acquires Seprafilm Adhesion Barrier (product rights, from Sanofi)
Snapshot
BAXTER INTERNATIONAL INC acquired Seprafilm Adhesion Barrier (product rights, from Sanofi) for approximately $342 million in cash in February 2020. The transaction was structured as all cash. Seprafilm Adhesion Barrier (product rights, from Sanofi) is a Acquired from Sanofi (France); product marketed primarily in the United States and other markets-based Surgical / adhesion prevention business.
- Acquirer
- BAXTER INTERNATIONAL INC
- Target
- Seprafilm Adhesion Barrier (product rights, from Sanofi)
- Value
- approximately $342 million in cash
- Date
- February 2020
- Type
- asset purchase
- Status
- ready
The deal at a glance
About this deal
BAXTER INTERNATIONAL INC acquired Seprafilm Adhesion Barrier (product rights, from Sanofi) for approximately $342 million in cash, a transaction completed in February 2020, structured as all cash. The deal was a asset purchase.
Seprafilm Adhesion Barrier (product rights, from Sanofi) operates in Surgical / adhesion prevention, is based in Acquired from Sanofi (France); product marketed primarily in the United States and other markets. Seprafilm Adhesion Barrier is a surgical product indicated for use in patients undergoing abdominal or pelvic laparotomy as an adjunct intended to reduce the incidence, extent and severity of postoperative adhesions between the abdominal wall and underlying viscera, acquired from Sanofi.
Expands Baxter's surgical and advanced surgery product portfolio with an established adhesion-prevention product.
Established surgical adhesion-prevention product extending Baxter's advanced surgery portfolio. Integrated into Baxter's Advanced Surgery business
No advisory firms have been disclosed for this transaction.